148580-01-2

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 148579-94-6 (25,3R,45,55,65)-2-(4-(hydroxymethyl)-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 21085-72-3 1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester 
• 148579-93-5 (2S,3R,4S,5S,6S)-2-(4-formyl-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 

Downstream Products

• 228412-64-4 N-<4-O--3-nitrobenzyloxycarbonyl>serine methyl ester 
• 228412-63-3 N-<4-O--3-nitrobenzyloxycarbonyl>glycine 
• 302937-42-4 (2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-(4-{[bis-(2-chloro-ethyl)-carbamoyloxy]-methyl}-2-nitro-phenoxy)-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 404387-08-2 (2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-[4-(2-methylamino-benzylcarbamoyloxymethyl)-2-nitro-phenoxy]-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 302937-44-6 (2S,3S,4S,5R,6S)-6-(4-{[Bis-(2-chloro-ethyl)-carbamoyloxy]-methyl}-2-nitro-phenoxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 228412-65-5 N-<4-O--3-nitrobenzyloxycarbonyl>acetoxymethylamine 
• 228412-68-8 5-fluoro-N-<4-O--3-nitrobenzyloxycarbonyl>-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethylamine 
• 228412-66-6 2-acetoxy-N-<4-O--3-nitrobenzyloxycarbonyl>glycine methyl ester 
• 228412-70-2 N-<4-O--3-nitrobenzyloxycarbonyl>-2-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)glycine methyl ester 
• 228412-67-7 5-fluoro-N-<4-O--3-nitrobenzyloxycarbonyl>-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethylamine 
• 228412-69-9 N-<4-O--3-nitrobenzyloxycarbonyl>-2-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)glycine methyl ester 
• 148580-25-0 N-[4-O-β-D-glucuronyl-3-nitrobenzyloxycarbonyl]doxorubicin 
• 1075719-60-6 3,4,5-triacetoxy-6-{4-[(2-(4-acetylamino-benzoylamino)-phenylcarbamoyl)oxymethyl]-2-nitro-phenoxy}-tetrahydro-2H-pyran-2-carboxylic acid methyl ester 
• 1224886-43-4 C₄₈H₆₂N₂O₁₆ 

Relevant academic research and scientific papers

Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy

A series of new prodrugs of daunorubicin and doxorubicin which are candidates for antibody-directed enzyme prodrug therapy (ADEPT) is reported. These compounds (25a,b,c and 32a,b,c) have been designed to generate cytotoxic drugs after activation with β-gl